4.2 Article

A randomized controlled trial comparing effects of a low-energy diet with n-3 polyunsaturated fatty acid supplementation in patients with non-alcoholic fatty liver disease

Journal

JOURNAL OF RESEARCH IN MEDICAL SCIENCES
Volume 24, Issue -, Pages -

Publisher

WOLTERS KLUWER MEDKNOW PUBLICATIONS
DOI: 10.4103/jrms.JRMS_282_18

Keywords

Body composition; diet; fatty acid omega-3; insulin resistance; nonalcoholic fatty liver disease; weight loss

Funding

  1. Food and Beverages Safety Research Center, Urmia University of Medical Sciences, Urmia, Iran

Ask authors/readers for more resources

Background: Weight loss is the cornerstone of NAFLD management, but weight maintenance is difficult. Some studies have suggested that n-3 polyunsaturated fatty acid (n-3 PUFA) might have beneficial effects in NAFLD. We aim to compare the effects of a low-energy diet with n-3 PUFA supplementation on liver enzymes, body composition, and cardiometabolic risk factors in NAFLD. Materials and Methods: The study was a randomized controlled trial conducted in Urmia in Iran from October 2016 to May 2017. One hundred and fourteen eligible patients were randomly assigned to one of the three following groups: low-energy diet group, n-3 PUFA supplementation (fish oil) group (1500 mg/d), or control group for 12 weeks. Liver enzymes, lipid profile, insulin resistance, and body composition were assessed before and after the intervention. Results: One hundred and four patients completed the study. All groups lost weight, but the reductions were greater in the diet group (2.97 +/- 2.79 kg, P = 0.001). The diet group had significant decreases in fat mass compared to other groups. Insulin resistance, total cholesterol, and low-density lipoprotein cholesterol significantly decreased only in the diet group, and patients who lost weight >= 4% showed significantly larger decreases in serum liver enzymes. N-3 PUFA had no beneficial effects on the study outcomes. Conclusion: We found that 1500 mg/d n-3 PUFA supplied for 12 weeks, in contrast to 3.40 +/- 2.98% weight loss, does not improve liver enzymes, body composition, and cardiometabolic risk factors in NAFLD patients.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available